Subramanian, Savanur and Madhavadas (NIMHANS, Bangalore) synthesized a 22-residue phospho-peptide spanning tau residues 50–71 (TPTEDGSEEPGSETSDAKpSpTPpT), selected via Immune Epitope Database predictions for B- and T-cell epitope propensity, raised rabbit polyclonal antibodies, and tested them in a 6-month-old Sprague-Dawley rat tauopathy model induced by intranasal okadaic acid (OA, 500 ng), a PP2A inhibitor that reliably triggers tau hyperphosphorylation and cognitive deficit .
Six IgG doses (1 mg IP on days 2–12) preceded Barnes maze training (days 6–10) and retention testing (day 15). OA + specific IgG reduced errors and latency versus OA + control IgG (reported as P<0.001 for behavior) and lowered p-tau from 72 to 54 pg/100 mg tissue (P<0.05); t-tau was unchanged (236, 226, 210, 274 pg/100 mg across Control/OA/OA+specific/OA+control) .
The authors also show dose-dependent ELISA binding of the antiserum to full-length tau and thioflavin-S evidence that Fab fragments block recombinant-tau aggregation, and they propose BBB-crossing FcR-mediated neuronal uptake plus neutralization of N-terminal tau fragments as mechanisms .
Skeptical checks: (1) n=6 per group is small; with p-tau SEM of 10–16, the 72→54 pg change is a modest effect (~25%) and behavioral P<0.001 claims from six animals per arm warrant independent replication. (2) No blinding of behavioral scoring or randomization details are reported. (3) Brain entry of the IP-administered antibody is asserted via analogy to prior work, not measured—no serum/CSF antibody titers or brain antibody quantification are shown. (4) The OA model induces acute PP2A inhibition rather than progressive AD-like pathology, so the cognitive rescue may reflect generic phosphatase-related mechanisms; conclusions about human tauopathies are inferential. (5) The p-tau ELISA epitope specificity (which phospho-sites the commercial kit detects) is unstated, so reduced "p-tau" may not include the pS68/pT69/pT71 cluster itself. (6) The in vitro aggregation assay uses heparin-induced fibrillization of recombinant tau, a simplified system. The authors do acknowledge that mechanism-of-action and further validation studies are needed .
What would falsify the conclusion: failure to replicate the Barnes maze and p-tau reduction with blinded scoring and larger n; demonstration that antibodies do not measurably enter the brain; or loss of benefit when tested in progressive transgenic tauopathy models rather than acute OA challenge.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.